Pérez-Santos, Martín2020-11-272020-11-272020-03-16Perez-Santos M. Evaluation of US2019070266 patent, treatment diabetic foot ulcers with Liraglutide. Alianzas y Tendencias BUAP. 2020 Mar 17;5(17):52. Available from: https://www.aytbuap.mx/publicaciones#h.38aimu2eznin2594-0627https://eoi.citefactor.org/10.11235/BUAP.05.17.04https://www.aytbuap.mx/editorial-517-cambios-urgentes-en-las-pr%C3%A1cticas-agr%C3%ADcolas-para-mitigar/evaluation-of-us2019070266-patent-treatment-diabetic-foot-ulcers-with-lirahttps://hdl.handle.net/20.500.12371/9396Diabetic foot ulcers are clinical complications that affect to a 15-25% of patients of type-2 diabetes mellitus and are responsible for more hospitalizations than any other complication of diabetes. Authors of US2019070266 patent propose a method for treatment of diabetic foot ulcers. US2019070266 describes a method that consists of the administration of Liraglutide, at a dose of 1.2-1.8 mg, in patients with type 2 diabetes and with at least one risk factor for vascular disease, such as microalbuminuria, proteinuria, hypertension, left ventricular hypertrophy, left ventricular systolic dysfunction, left ventricular diastolic dysfunction and ankle/brachial index <0.9. The results of the clinical trials support the therapy’s efficacy; however, the invention is not new considering art state, whereby, new studies will be necessary to determine other administration routes, e.g. topical, dose and time of administration of Liraglutide.spaLiraglutidediabetic footpatentdiabetesulcerArtículo